Abstract Number: 1143 • ACR Convergence 2024
Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous systemic autoimmune diseases with a worldwide incidence ranging from 0.116 to 1.9 and a prevalence from 2.4 to…Abstract Number: 1164 • ACR Convergence 2024
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity. Correlations of demographic and clinical features with pathological findings remain underexplored. In addition,…Abstract Number: 1735 • ACR Convergence 2024
High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial
Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…Abstract Number: 2077 • ACR Convergence 2024
Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts
Background/Purpose: The family of Janus kinases (JAK1, JAK2, JAK3, TYK2) mediate signal transduction from cytokine receptors through phosphorylation and activation of intracellular signaling pathways and…Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…Abstract Number: 0005 • ACR Convergence 2024
Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
Background/Purpose: Myositis autoantibodies are important clinical biomarkers however, around 40% of patients with juvenile myositis (JM) are classified as ‘autoantibody negative’ (1) and therefore cannot…Abstract Number: 0338 • ACR Convergence 2024
Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Background/Purpose: Anti-melanoma differentiation-associated protein 5 antibody associated dermatomyositis (Anti-MDA5 DM) is known to be an aggressive disease. Earlier cohorts reported a 1-year mortality of 38%-57%, with rapidly…Abstract Number: 1145 • ACR Convergence 2024
Clinico-Immunological Profile and Treatment Outcomes of Clinically Significant Diaphragmatic Weakness in Patients with Idiopathic Inflammatory Myopathies: Results from the Largest Single-Center Cohort of 16 Cases
Background/Purpose: Diaphragmatic myositis is rarely reported in patients with idiopathic inflammatory myopathy (IIM) but is associated with high morbidity and mortality. Epidemiology, spectrum of clinical…Abstract Number: 1165 • ACR Convergence 2024
Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Cardiac involvement, such as myocarditis, in idiopathic inflammatory myopathies (IIM) is a negative prognostic factor associated with increased mortality. The gold standard for myocarditis…Abstract Number: 1749 • ACR Convergence 2024
Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease
Background/Purpose: Treating autoimmune diseases like Systemic Lupus erythematosus (SLE), Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc) is challenging and often requires life-long immunosuppressive therapy.…Abstract Number: 2078 • ACR Convergence 2024
Increased RAGE Expression in Myositis
Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…Abstract Number: 2669 • ACR Convergence 2024
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…Abstract Number: 0088 • ACR Convergence 2024
Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease indications.…Abstract Number: 0340 • ACR Convergence 2024
Progressive Pulmonary Fibrosis Predicts Mortality in Myositis-Associated Interstitial Lung Disease
Background/Purpose: Myositis-associated interstitial lung disease (MA-ILD) is a complex condition with a variable prognosis and diverse clinical manifestations. The 2022 ATS/ERS/JRS/ALAT criteria for PPF provide…Abstract Number: 1146 • ACR Convergence 2024
Impact of COVID-19 on Myositis Testing Trends
Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 28
- Next Page »